The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
Open accessAbstract
BACKGROUND & AIMS Overall survival (OS) is a composite clinical endpoint in hepatocellular carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating patient's mortality. The ALBI grade is a recently described index of liver dysfunction in hepatocellular carcinoma, based solely on albumin and bilirubin levels. Whilst accurate, this score lacks cross-validation, especially in intermediate stage HCC, where OS is highly heterogeneous. METHODS We evaluated the prognostic accuracy of the ALBI grade in estimating OS in a large, multi-centre study of 2426 patients, including a large proportion of intermediate stage patients treated with chemoembolization (n=1461) accrued from Europe, the United States and Asia. RESULTS Analysis of survival by primary treatment modality confirmed the ALBI grade as a significant predictor of patient OS after surgical resection (p<0.001), transarterial chemoembolization (p<0.001) and sorafenib (p<0.001). Stratification by Barcelona Clinic Liver Cancer stage confirmed the independent prognostic value of the ALBI across the diverse stages of the disease, geographical regions of origin and time of recruitment to the study (p<0.001). CONCLUSIONS In this large, multi-centre retrospective study, the ALBI grade satisfied the criteria for accuracy and reproducibility following statistical validation in Eastern and Western HCC patients, including those treated with chemoembolization. Consideration should be given to the ALBI grade as a stratifying biomarker of liver reserve in routine clinical practice. LAY SUMMARY Liver failure is a key determinant influencing the natural history of hepatocellular carcinoma (HCC). In this large multi-centre study we externally validate a novel biomarker of liver functional reserve, the ALBI grade, across all the stages of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Harrell (2015) · Springer Series in Statistics · doi:10.1007/978-3-319-19425-7 · Cited by 6,878
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,783
Model for end-stage liver disease (MELD) and allocation of donor livers
Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P., Kremers, W., Lake, J., Howard, T., Merion, R. M., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50016 · Cited by 2,528
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Burroughs, A., Dufour, J.-F., Galle, P., Mazzaferro, V., Piscaglia, F., Raoul, J., Sangro, B., & Bolondi, L. (2013) · Seminars in Liver Disease · doi:10.1055/s-0032-1329906 · Cited by 641
de Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
rms: Regression Modeling Strategies
Harrell Jr, F. E. (2009) · CRAN: Contributed Packages · doi:10.32614/cran.package.rms · Cited by 458
Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors
Schütte, K., Bornschein, J., & Malfertheiner, P. (2009) · Digestive Diseases · doi:10.1159/000218339 · Cited by 441
CHOLONGITAS, E., PAPATHEODORIDIS, G. V., VANGELI, M., TERRENI, N., PATCH, D., & BURROUGHS, A. K. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02691.x · Cited by 420
Assessment of Prognosis of Cirrhosis
Durand, F., & Valla, D. (2008) · Seminars in Liver Disease · doi:10.1055/s-2008-1040325 · Cited by 410
Kadalayil, L., Benini, R., Pallan, L., O'Beirne, J., Marelli, L., Yu, D., Hackshaw, A., Fox, R., Johnson, P., Burroughs, A. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt247 · Cited by 370
Singh, S., Fujii, L. L., Murad, M. H., Wang, Z., Asrani, S. K., Ehman, R. L., Kamath, P. S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.034 · Cited by 352
Non-invasive diagnosis of liver fibrosis and cirrhosis
Lurie, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11567 · Cited by 352
Bolondi, L., Burroughs, A. K., Dufour, J.-F., Galle, P. R., Mazzaferro, V., Piscaglia, F., Raoul, J., & Sangro, B. (2012) · BORIS (University Library Bern) · Cited by 320
Cholongitas, E., Marelli, L., Shusang, V., Senzolo, M., Rolles, K., Patch, D., & Burroughs, A. K. (2006) · Liver Transplantation · doi:10.1002/lt.20824 · Cited by 302
Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems
Liu, P.-H., Hsu, C.-Y., Hsia, C.-Y., Lee, Y.-H., Su, C.-W., Huang, Y.-H., Lee, F.-Y., Lin, H.-C., & Huo, T.-I. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.029 · Cited by 263
Hiraoka, A., Kumada, T., Michitaka, K., Toyoda, H., Tada, T., Ueki, H., Kaneto, M., Aibiki, T., Okudaira, T., Kawakami, T., et al. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13250 · Cited by 245
Pinato, D. J., Stebbing, J., Ishizuka, M., Khan, S. A., Wasan, H. S., North, B. V., Kubota, K., & Sharma, R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.022 · Cited by 181
Self-citationHucke, F., Pinter, M., Graziadei, I., Bota, S., Vogel, W., Müller, C., Heinzl, H., Waneck, F., Trauner, M., Peck-Radosavljevic, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.002 · Cited by 159
Pressiani, T., Boni, C., Rimassa, L., Labianca, R., FAGIUOLI, S., Salvagni, S., Ferrari, D., Cortesi, E., Porta, C., Mucciarini, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds343 · Cited by 154
Chan, A. W. H., Kumada, T., Toyoda, H., Tada, T., Chong, C. C. N., Mo, F. K. F., Yeo, W., Johnson, P. J., Lai, P. B. S., Chan, A. T. �., et al. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13291 · Cited by 129
Cucchetti, A., Cescon, M., Golfieri, R., Piscaglia, F., Renzulli, M., Neri, F., Cappelli, A., Mazzotti, F., Mosconi, C., Colecchia, A., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.025 · Cited by 126
Intermediate hepatocellular carcinoma: current treatments and future perspectives
Dufour, J., Bargellini, I., Maria, N. D., SIMONE, P. D., Goulis, I., & Marinho, R. T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt054 · Cited by 115
Transarterial Chemoembolization and Radioembolization
Salem, R., & Sangro, B. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394142 · Cited by 101
Pinato, D. J., Arizumi, T., Allara, E., Jang, J. W., Smirne, C., Kim, Y. W., Kudo, M., Pirisi, M., & Sharma, R. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.037 · Cited by 68
Self-citationPinato, D. J., Karamanakos, G., Arizumi, T., Adjogatse, D., Kim, Y. W., Stebbing, J., Kudo, M., Jang, J. W., & Sharma, R. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12992 · Cited by 36
Self-citationProcopeț, B., Tantau, M. V., & Bureau, C. (2013) · PubMed · Cited by 34
Curative therapies for hepatocellular carcinoma: an update and perspectives
Sacco, R., Antonucci, M., Bresci, G., Corti, A., Giacomelli, L., Mismas, V., Rainieri, M., Romano, A., Eggenhöffner, R., Tumino, E., et al. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1123625 · Cited by 9
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“Other measures including the MELD score or MELD including sodium (MELD-Na), ALBI score, [171] indocyanine green kinetics, [172] and liver stiffness measurement by transient elastography [173] are associated with risk of postresection hepatic decompensation and may also be used to refine patient…”
Metadata
- Authors
- Pinato, D. J., Sharma, R., Allara, E., Yen, C., Arizumi, T., Kubota, K., Bettinger, D., Jang, J. W., Smirne, C., Kim, Y. W., Kudo, M., Howell, J., Ramaswami, R., Burlone, M. E., Guerra, V., Thimme, R., Ishizuka, M., Stebbing, J., Pirisi, M., & Carr, B. I.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 66
- Issue
- 2
- Pages
- 338-346
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2522516475
- Cited by
- 413
- References
- 35
- FWCI
- 19.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.